Prothena Corporation plc (NASDAQ:PRTA) presented new preclinical data from its dual Aβ/tau and tandem C-terminal α-synuclein vaccine programs in Alzheimer's disease (AD) and Parkinson's disease (PD), respectively.
- The data were presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022).
- The Company plans for an IND for the AD vaccine candidate in 2023.
- Related: Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B.
- The presentation on preclinical data demonstrates Prothena's dual Aβ/tau vaccine for Alzheimer's, generated anti-Aβ and anti-tau antibodies to enable phagocytosis of Aβ and neutralize tau.
- Preclinical data from the tandem C-terminal α-synuclein vaccine for Parkinson's produces robust binding to pathogenic α-synuclein and inhibition of uptake of soluble α-synuclein aggregates into cells.
- Price Action: PRTA shares closed 4.35% higher at $33.33 on Tuesday.
